Nachrichten zur Amicus Therapeutics Inc. Aktie

Will Amicus Therapeutics (FOLD) Report Negative Earnings Next Week? What You Should Know

Amicus Therapeutics (FOLD) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…

Newell Brands, Amicus fall; HubSpot, Cognex rise

NEW YORK (AP) — Stocks that traded heavily or had substantial price changes Friday:...…

Artelo Biosciences leads healthcare gainers; Conformis and Amicus Therapeutics among losers

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Amicus Reports Disappointing Tests Results for Pompe Disease Drug

Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…

Amicus Therapeutics downgraded to neutral from overweight at J.P. Morgan

Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...…

SVB Leerink, J.P. Morgan downgrade Amicus stock after Phase 3 data for rare disease drug comes out

Shares of Amicus Therapeutics Inc. were down 23.1% in premarket trading on Friday, the day after the company said…

Amicus Therapeutics cut to Neutral at Cantor citing PROPEL trial data

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Amicus Therapeutics (FOLD) Updates on Phase 3 PROPEL Topline Results - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Amicus Therapeutics (FOLD) Presents At 17th Annual Virtual WORLDSymposium 2021 - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

John Crowley, Amicus Therapeutics, discusses drug trial results for Pompe disease

CNBC Meg Tirrell talks with Amicus Therapeutics CEO John Crowley about trial results for a drug to treat Pompe disease.…

Amicus after announcing late-stage data for AT-GAA trial in Pompe disease

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Amicus releases phase 3 results in Pompe disease trial

CNBC's senior health and science reporter Meg Tirrell reports Amicus showed results in its phase 3 trial to address Pompe…

AMICUS THERAPEUTICS, INC.: 8-K Report

FORM 8-K...…

Amicus announces early-stage interim data for AT-GTX-502 in Batten disease

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

AMICUS THERAPEUTICS, INC.: 8-K Report

FORM 8-K...…

Amicus Therapeutics Presents Positive Preclinical Fabry Disease Gene Therapy Data at the 17th Annual WORLDSymposium™ 2021

Amicus Optimized Transgene Show Greater Substrate Reduction than Wild Type Construct Across All Tissues and Doses...…

Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene Therapy at the 17th Annual WORLDSymposium™ 2021

Initial Data Suggest Early Signs of Disease Stabilization in Children with Fatal Neurologic Disease...…

Amicus files for shelf registration of 2.5M warrants for share purchases

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Implied Volatility Surging for Amicus Therapeutics (FOLD) Stock Options

Investors need to pay close attention to Amicus Therapeutics (FOLD) stock based on the movements in the options market lately....…

Amicus Therapeutics Announces Presentations and Posters at the 17th Annual WORLDSymposium™ 2021

CRANBURY, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused…

Amicus Therapeutics reports preliminary 2020 revenue and 2021 outlook

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

AMICUS THERAPEUTICS, INC.: 8-K Report

FORM 8-K...…

Amicus Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

CRANBURY, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley,…

Microsoft, Google, Cisco, Dell join legal battle against hacking company NSO

Tech giants including Microsoft and Google on Monday joined Facebooks legal battle against hacking company NSO, filing an amicus brief…

Google, Cisco, and VMware join Microsoft to oppose NSO Group in WhatsApp spyware case

A coalition of companies have filed an amicus brief in support of a legal case brought by WhatsApp against Israeli…

Microsoft, Google, Cisco, VMware join legal battle against hacking company NSO

Tech giants Microsoft, Alphabet , Cisco, and VMware on Monday joined Facebooks legal battle against hacking company NSO, filing an…

Sarepta, Amicus Top Biotech Picks Ahead Of Key Binary Events: Analyst

Biopharma stocks are risky investment bets that sway wildly in reaction to catalytic events. Binary events scheduled for Amicus Therapeutics,…

Amicus Therapeutics (FOLD) Catches Eye: Stock Jumps 8.1%

Amicus Therapeutics (FOLD) saw a big move last session, as its shares jumped more than 8% on the day, amid…

House Democrat Calls To Exclude 126 Republicans From Next Congress For Supporting Texas Lawsuit

Rep. Bill Pascrell urged Speaker Nancy Pelosi to refuse to seat anyone who signed an amicus brief in support of…

Amicus Therapeutics Named a Great Place to Work-Certified™ Company in 2020

CRANBURY, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused…

Amicus (FOLD) Initiates Rolling BLA Submission for AT-GAA

Amicus (FOLD) initiates a rolling biologics license application (BLA) submission to the FDA for AT-GAA, for the treatment of late…

AMICUS THERAPEUTICS, INC.: 8-K Report

FORM 8-K...…

Amicus Therapeutics Appoints Michael A. Kelly to its Board of Directors

CRANBURY, N.J., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced the election and appointment…

Gray Files Supreme Court Brief Supporting Modernized Television Station Ownership Rules

Atlanta, Georgia, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Gray Television, Inc. (“Gray,” “we,” or “our”) (NYSE: GTN) announced…

Amicus Therapeutics (FOLD) Presents At Credit Suisse 29th Annual Virtual Healthcare Conference - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q3 2020 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Amicus Therapeutics (FOLD) Reports Q3 Loss, Tops Revenue Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -10.00% and 3.69%, respectively, for the quarter ended September 2020. Do…

Amicus Therapeutics, Inc. 2020 Q3 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Amicus Therapeutics EPS misses by $0.04, beats on revenue

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

AMICUS THERAPEUTICS, INC.: 8-K Report

FORM 8-K...…

Amicus Therapeutics to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference

CRANBURY, N.J., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley,…

Amicus Therapeutics (FOLD) Investor Presentation - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Amicus Therapeutics (FOLD) Presents Interim Data for CLN6 Gene Therapy at Child Neurology Society Meet - Slideshow

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Amicus Therapeutics Announces Additional Positive Interim Clinical Data for CLN6 Batten Disease Gene Therapy at 49th Annual Meeting of the Child Neurology Society

Data Continue to Support Meaningful Effect on Motor and Language Function in Children with Fatal Neurologic Disease Data Continue to…